Recent studies demonstrate that the fibroblast growth factor-21 (FGF21), an hepatokine, is partly responsible for the beneficial actions of an exogenously administered NRG1 fusion protein on obesity-related metabolic outcomes [47]. This evidence concerns the gene FGF21 and obesity disorder.